Form 4: UTHR Director Sells All Shares After Option Exercise

United Therapeutics Director Louis W. Sullivan exercised stock options and subsequently sold all beneficially owned common stock through a trust on December 22, 2025.

Summary

• Director Louis W. Sullivan of United Therapeutics Corp (UTHR) reported transactions on December 22, 2025, executed under a Rule 10b5-1(c) plan.
• Sullivan acquired 3,230 shares of common stock by exercising stock options at an exercise price of $183.98 per share.
• An additional 2,720 shares of common stock were acquired through option exercise at $229.81 per share.
• Following these acquisitions, Sullivan disposed of 1,087 shares at a weighted average price of $511.2231 per share.
• A further 4,863 shares were sold at a weighted average price of $512.3383 per share.
• After these transactions, Sullivan's indirect beneficial ownership through a trust is 0.00 shares.
• All securities are held indirectly by a trust over which the reporting person has sole investment and voting power.

Sentiment

Score: 4

Explanation: The director fully divested all beneficially owned shares after exercising options. While executed under a Rule 10b5-1 plan, a complete sell-off by an insider can be viewed with slight caution by investors, though it's a common practice for long-serving directors to monetize equity.

Positives

• The director realized significant gains by exercising options at lower prices ($183.98 and $229.81) and selling shares at substantially higher market prices (over $511).
• The transactions were executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary sale, which can mitigate concerns about opportunistic insider selling.

Negatives

• The director fully divested all beneficially owned common stock (0.00 shares remaining), which could be interpreted by some investors as a lack of confidence in the company's future prospects, despite being a pre-planned sale.

Future Outlook

This filing details an individual insider transaction and does not provide forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 reports an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• The securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.

Stakeholder Impact

• Shareholders may view the complete divestment of shares by a director as a potential negative signal, even if executed under a 10b5-1 plan.
• The transactions demonstrate the monetization of long-held equity incentives by a director.

Key Dates

Recommendation

Director Louis W. Sullivan executed pre-planned option exercises and subsequent sales, divesting all beneficially owned shares. While a full divestment by a director can raise questions, the transaction was made pursuant to a Rule 10b5-1 plan, suggesting it was scheduled in advance rather than a reaction to new information. Investors should monitor future insider activity and company performance for further insights.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Share Sale, Director Transaction, Louis W. Sullivan, 10b5-1 Plan